| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$221 |
Trading Halt
|
25 Aug 2025 9:32AM |
$1.580 |
$1.675 |
risen by
6.01%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Victory Metals Limited (VTM) requested a trading halt effective December 19, 2019.
- The trading halt is pending an announcement by the company.
- The halt was requested to maintain a fair and orderly market.
- Trading will resume on December 23, 2019, or upon release of the company's announcement.
- The Australian Securities Exchange (ASX) listed this request under Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| XRF Scientific Limited (XRF) ORDINARY FULLY PAID |
Industrials |
$262 |
Cleansing Statement
|
25 Aug 2025 9:32AM |
$2.230 |
$1.830 |
fallen by
17.94%
|
|
| GR Engineering Services Limited (GNG) ORDINARY FULLY PAID |
Materials |
$1,029 |
Full Year Statutory Accounts FY25
|
25 Aug 2025 9:31AM |
$4.410 |
$6.040 |
risen by
36.96%
|
|
GNG - Price-sensitive ASX Announcement
Full Release
Key Points
- GR Engineering Services Limited released its Full Year Statutory Accounts for FY25.
- The report includes comprehensive financial statements: profit or loss, financial position, cash flows, and changes in equity.
- Significant accounting policies, revenue recognition, and financial management practices are discussed.
- The accounts provide information on key management remuneration and related party transactions.
- Operational highlights and major projects of the year are summarized.
- Risk management strategies and corporate governance practices are outlined.
- Income tax, expenses, and financial instruments are detailed with supporting notes.
- Critical accounting estimates, provisions, and contingencies are disclosed.
- Auditor’s independence and remuneration are reported.
- Segment reporting and detailed notes to the financial statements provide additional insights into company operations for FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Provaris Energy Ltd (PV1) ORDINARY FULLY PAID |
Energy |
$8 |
Trading Halt
|
25 Aug 2025 9:31AM |
$0.023 |
$0.007 |
fallen by
69.57%
|
|
PV1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Provaris Energy Ltd requested a trading halt.
- The trading halt is pending an announcement on capital raising.
- The halt remains until the announcement or 27 August 2025.
- Request made under ASX Listing Rule 17.1.
- No reason was found to deny the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$25 |
HERACLES clinical trial Update 3
|
25 Aug 2025 9:30AM |
$0.115 |
$0.080 |
fallen by
30.43%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- HERACLES is a Phase 1b/2 clinical trial evaluating SOFRA-001 in late-stage solid cancer patients.
- The trial aims to assess safety, tolerability, and initial efficacy of SOFRA-001.
- Early results suggest SOFRA-001 has a favorable safety profile, with no dose-limiting toxicities observed.
- Some patients have shown disease stabilization and tumor shrinkage.
- Recruitment and patient dosing are ongoing, with continued monitoring and data collection.
- Noxopharm Limited remains committed to developing SOFRA-001 as a new therapeutic option for advanced cancer patients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Far Limited (FAR) ORDINARY FULLY PAID |
Energy |
$28 |
Half Year Report and Accounts
|
25 Aug 2025 9:30AM |
$0.390 |
$0.305 |
fallen by
21.79%
|
|
FAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Covers the six-month period ended 31 December 2022.
- Focuses on Senegal and The Gambia exploration assets.
- Details operational progress, including license renewals and upcoming work commitments.
- Reports on financial position, cash flow, and expenditure control.
- Addresses corporate governance, including changes in board composition.
- Highlights ongoing risk management in light of market and operational uncertainties.
- Emphasises commitment to creating shareholder value and advancing exploration in West Africa.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argent Biopharma Limited (RGT) ORDINARY FULLY PAID |
Health Care |
$5 |
U.S. In Vivo Study Supports ArtemiC Efficacy
|
25 Aug 2025 9:30AM |
$0.130 |
$0.039 |
fallen by
70%
|
|
RGT - Price-sensitive ASX Announcement
Full Release
Key Points
- RGT and Argent Biopharma Limited announced positive results from a U.S.-based in vivo study on ArtemiC.
- The study demonstrates ArtemiC's efficacy in reducing disease symptoms and improving recovery in a preclinical COVID-19 animal model.
- ArtemiC is a novel oral spray formulation containing four active ingredients, including artemisinin and curcumin, aimed at reducing inflammation and mitigating cytokine storms.
- The in vivo study was conducted at a leading U.S. research institution using a validated COVID-19 animal model.
- Results showed statistically significant improvements in disease index, body weight, and survival rates in ArtemiC-treated animals compared to controls.
- No adverse reactions were observed in any of the treated animals throughout the study.
- The study supports the claimed anti-inflammatory and immune-modulatory effects of ArtemiC, aligning with previous clinical trial data from other regions.
- Regeneus and Argent Biopharma see these results as supporting further clinical development and commercialization efforts for ArtemiC in the U.S. and globally.
- The announcement affirms the companies' commitment to advancing novel therapies for diseases involving excessive inflammation, like COVID-19.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,098 |
1H25 Results Release
|
25 Aug 2025 9:29AM |
$3.020 |
$2.800 |
fallen by
7.28%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Regal Partners Limited will release its 1H25 financial results on 14 August 2024.
- A results briefing will be held via live webcast at 10:00am (AEST) on the release date.
- Instructions for webcast registration are provided in the announcement.
- Results materials and investor presentation will be available on the ASX and Regal Partners website.
- Investor and media contact details are included for further inquiries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| XRF Scientific Limited (XRF) ORDINARY FULLY PAID |
Industrials |
$262 |
Application for quotation of securities - XRF
|
25 Aug 2025 9:29AM |
$2.230 |
$1.830 |
fallen by
17.94%
|
|
| Qmines Limited (QML) ORDINARY FULLY PAID |
Materials |
$46 |
Strong Sulphides Intersected at Sulphide City
|
25 Aug 2025 9:29AM |
$0.054 |
$0.060 |
risen by
11.11%
|
|
QML - Price-sensitive ASX Announcement
Full Release
Key Points
- Qmines Limited (QML) reported strong sulphide intersections at Sulphide City, part of the Mt Chalmers Project.
- Recent drilling encountered significant copper, gold, silver, and zinc mineralisation.
- Mineralisation was intersected outside the current resource envelope, suggesting resource growth potential.
- All holes at Sulphide City intersected notable sulphide mineralisation, with some best-ever results.
- QML intends to conduct downhole geophysical surveys and further drilling to delineate mineralisation.
- The results highlight the prospectivity of Mt Chalmers for base and precious metals.
- The company’s exploration results support the progression towards development and eventual production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strategic Energy Resources Limited (SER) ORDINARY FULLY PAID |
Materials |
$9 |
Notice of Extraordinary General Meeting/Proxy Form
|
25 Aug 2025 9:29AM |
$0.005 |
$0.125 |
risen by
2,400%
|
|
| Alligator Energy Limited (AGE) ORDINARY FULLY PAID |
Energy |
$195 |
Samphire Field Recovery Trial PEPR Approved
|
25 Aug 2025 9:28AM |
$0.022 |
$0.044 |
risen by
100%
|
|
AGE - Price-sensitive ASX Announcement
Full Release
Key Points
- AGE's Program for Environment Protection and Rehabilitation (PEPR) for the Samphire Field Recovery Trial (FRT) has been approved.
- Approval received from South Australian Department for Energy and Mining.
- Allows proceeding with an in-situ recovery (ISR) uranium extraction field recovery trial.
- Samphire Uranium Project is located near Whyalla, South Australia.
- Approval follows comprehensive baseline studies and regulatory engagement.
- Trial will collect technical, environmental, and operational data.
- Data will support future Mining Lease Application and potential project development.
- Trial aims to demonstrate safe and effective ISR uranium extraction.
- Represents a significant regulatory and project milestone for AGE.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argent Minerals Limited (ARD) ORDINARY FULLY PAID |
Materials |
$39 |
Exploration Update over Kempfield Drilling Program
|
25 Aug 2025 9:28AM |
$0.020 |
$0.023 |
risen by
15%
|
|
ARD - Price-sensitive ASX Announcement
Full Release
Key Points
- Argent Minerals Limited has provided an exploration update for its Kempfield Drilling Program.
- The update focuses on the progress and objectives of the current diamond drilling campaign.
- Drilling targets high-grade polymetallic mineral zones containing silver, lead, zinc, and gold.
- Details are provided on the holes completed, planned drilling, and initial geological observations.
- Lithological and mineralization data from drilling are summarized with preliminary interpretations.
- The program aims to expand the Kempfield resource and improve understanding of the deposit.
- Assay results for recent drill holes are pending and will be reported in future updates.
- Argent Minerals remains committed to systematic exploration and resource growth at Kempfield.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,824 |
Notification of cessation of securities - NWS
|
25 Aug 2025 9:28AM |
$53.870 |
$47.850 |
fallen by
11.18%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,098 |
Dividend/Distribution - RPL
|
25 Aug 2025 9:28AM |
$3.020 |
$2.800 |
fallen by
7.28%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,824 |
Notification of cessation of securities - NWS
|
25 Aug 2025 9:28AM |
$53.870 |
$47.850 |
fallen by
11.18%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,098 |
Appendix 4D and Interim Financial Report, 6cps Dividend
|
25 Aug 2025 9:28AM |
$3.020 |
$2.800 |
fallen by
7.28%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Regal Partners Limited released its Appendix 4D and Interim Financial Report for the half-year ended 30 June 2023.
- Statutory net profit after tax was $7.1 million; underlying net profit after tax was $13.0 million.
- A fully franked interim dividend of 6.0 cents per share was declared.
- The interim dividend has a record date of 31 August 2023 and will be paid on 14 September 2023.
- Fund growth was strong during the reporting period.
- RPL continued to invest in new strategies and platform developments.
- The successful acquisition of PM Capital Limited was completed.
- The report details financial performance, operational updates, risk management, and strategic direction.
- RPL is positioned for further growth and continued shareholder returns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$16 |
Trading Halt
|
25 Aug 2025 9:27AM |
$0.071 |
$0.045 |
fallen by
36.62%
|
|
NIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Nimy Resources Limited (NIM) requested a trading halt effective 17 June 2024.
- The trading halt relates to a pending announcement of a capital raising.
- Trading halt granted by ASX to ensure market is fully informed.
- The halt will remain until 19 June 2024 or until the announcement is made.
- The company is not aware of any reason the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EVT Limited (EVT) ORDINARY FULLY PAID |
Communication Services |
$2,347 |
Year End Results Presentation
|
25 Aug 2025 9:27AM |
$17.140 |
$14.440 |
fallen by
15.75%
|
|
EVT - Price-sensitive ASX Announcement
Full Release
Key Points
- Year ended 30 June 2025 results announced.
- Entertainment division affected by Hollywood strike, flat revenue growth.
- Q4 recovery with strong admissions and EBITDA in Australia and NZ.
- Travel division, particularly hotels, showed record EBITDA and revenue growth.
- Strategic focus on hotel expansion and property asset divestment.
- Future growth expected, contingent on film performance and weather.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EVT Limited (EVT) ORDINARY FULLY PAID |
Communication Services |
$2,347 |
Year End Results Presentation
|
25 Aug 2025 9:27AM |
$17.140 |
$14.440 |
fallen by
15.75%
|
|
EVT - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue increased by 1.3% to $1,236.9 million.
- Hotels segment outperformed market, with revenue up by 1.5%.
- Entertainment revenue remained flat due to Hollywood strike impacts.
- Thredbo resort achieved commendable results despite poor weather.
- Overall Group EBITDA grew by 6.3% to $160.8 million.
- Record Hotels EBITDA reached $106.2 million, up by 4.7%.
- Strategic progress seen in 'Fewer, Better' cinema strategy.
- Non-core property asset divestment continues.
- Expectations for continued growth subject to film performance and weather.
- Final dividend declared at 22 cents per share, fully franked.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$28 |
FY25 Results and Investor Briefing Details
|
25 Aug 2025 9:27AM |
$0.098 |
$0.100 |
risen by
2.04%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,880 |
First site initiated for Neuren's PMS Phase 3 trial
|
25 Aug 2025 9:27AM |
$17.170 |
$22.720 |
risen by
32.32%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- First investigational site initiated in the US for Phase 3 trial of NNZ-2591 for PMS.
- Received IRB approval for the trial.
- First-ever Phase 3 trial in Phelan-McDermid syndrome.
- Approximately 160 children aged 3-12 will participate in a 13-week trial.
- Participants may continue treatment in a 12-month open-label extension.
- Trial is fully funded by Neuren's cash reserves.
- Regulatory alignment achieved with US FDA on trial design.
- Neuren's programs have orphan drug designation in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,880 |
First site initiated for Neuren's PMS Phase 3 trial
|
25 Aug 2025 9:27AM |
$17.170 |
$22.720 |
risen by
32.32%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- First investigational site initiated in the US for Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome.
- The Phase 3 trial is for NNZ-2591, targeting Phelan-McDermid syndrome (PMS).
- The trial is randomized, double-blind, placebo-controlled, spanning 13 weeks.
- 160 children aged 3-12 with PMS will be assessed.
- Participants may continue treatment in a 12-month open-label extension.
- Neuren is funding the trial from existing cash reserves.
- Phelan-McDermid syndrome is a serious neurodevelopmental disorder with no approved treatments.
- The trial received approval from the Institutional Review Board (IRB).
- Neuren's programs have orphan drug designation in the US.
- The trial design was aligned with the US FDA during End of Phase 2 and subsequent Type C meetings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$13 |
Way2VAT Renews Key Financing Facility
|
25 Aug 2025 9:27AM |
$0.008 |
$0.048 |
risen by
500%
|
|
| WAM Income Maximiser Limited (WMX) ORDINARY FULLY PAID |
Financials |
$324 |
Extraordinary General Meeting Chairman's Address
|
25 Aug 2025 9:26AM |
$1.650 |
$1.675 |
risen by
1.52%
|
|
Call 1300 880 160
Start a chat
Schedule a call
